Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY
Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY
Financial Results for the Year Ended December 31, 2023
For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a net loss of $28.9 million, or a net loss per common share of $63.43, for the same period in 2022.
截至2023年12月31日止年度的財務業績
截至2023年12月31日的財年，該公司報告的淨虧損爲6,040萬美元，普通股每股淨虧損爲89.61美元，而2022年同期的淨虧損爲2,890萬美元，普通股每股淨虧損爲63.43美元。
During the year ended December 31, 2023, net cash used in operating activities was $52.4 million, compared to $36.1 million for the same period in 2022.
在截至2023年12月31日的年度中，用於經營活動的淨現金爲5,240萬美元，而2022年同期爲3,610萬美元。
Kyverna reported $57.5 million in cash, cash equivalents, and available-for-sale marketable securities as of December 31, 2023. Subsequent to December 31, 2023, the Company raised approximately $366.9 million in gross proceeds from its initial public offering that was completed in February 2024.
截至2023年12月31日，Kyverna報告了5,750萬美元的現金、現金等價物和可供出售的有價證券。2023年12月31日之後，公司從2024年2月完成的首次公開募股中籌集了約3.669億美元的總收益。
譯文內容由第三人軟體翻譯。